Palisade Bio is a biopharmaceutical company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. The Company believes that addressing the disruption of the intestinal barrier can fundamentally change the way diseases are treated and establish new standards of patient care.

The Company recently entered into an exclusive worldwide licensing agreement with Giiant Pharma, Inc. for multiple oral drug candidates targeting inflammatory bowel disease (IBD) and a proprietary precision delivery technology platform. IBD represents a multi-billion-dollar market opportunity in need of innovative approaches, with current therapies achieving a clinical remission rate of less than 20% on average.

Palisade Bio’s lead program, PALI-2108 is a microbiota-activated PDE4 inhibitor prodrug being developed for the treatment of moderate-to-severe ulcerative colitis and is advancing toward the completion of IND-enabling studies and an IND filing. The Company’s second lead program, PALI-1908, is being evaluated in preclinical development for the treatment of fibro stenotic Crohn’s Disease.